CVN424 Phase 3 Trial for Parkinson's Disease

CVN424 Phase 3 Trial for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CVN424 Phase 3 Trial for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>CVN424 (GPR6 antagonist)</td>
</tr>
<tr>
<td class="label">Primary target</td>
<td>GPR6 (indirect)</td>
</tr>
<tr>
<td class="label">Receptor activation</td>
<td>None</td>
</tr>
<tr>
<td class="label">Dyskinesia risk</td>
<td>Potential reduction</td>
</tr>
<tr>
<td class="label">Impulse control disorder</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Hallucinations</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Sleep attacks</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Receptor desensitization</td>
<td>Different mechanism</td>
</tr>
<tr>
<td class="label">Arm</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">CVN424</td>
<td>60 mg once daily</td>
</tr>
<tr>
<td class="label">Placebo</td>
<td>Matching tablet</td>
</tr>
<tr>
<td class="label">System Organ Class</td>
<td>Expected Frequency</td>
</tr>
<tr>
<td class="label">Nervous system</td>
<td>Headache (15-20%)</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Nausea (10-15%)</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Dry mouth (5-10%)</td>
</tr>
<tr>
<td class="label">General</td>
<td>Fatigue (5-10%)</td>
</tr>
<tr>
<td class="lab

CVN424 Phase 3 Trial for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CVN424 Phase 3 Trial for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>CVN424 (GPR6 antagonist)</td>
</tr>
<tr>
<td class="label">Primary target</td>
<td>GPR6 (indirect)</td>
</tr>
<tr>
<td class="label">Receptor activation</td>
<td>None</td>
</tr>
<tr>
<td class="label">Dyskinesia risk</td>
<td>Potential reduction</td>
</tr>
<tr>
<td class="label">Impulse control disorder</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Hallucinations</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Sleep attacks</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Receptor desensitization</td>
<td>Different mechanism</td>
</tr>
<tr>
<td class="label">Arm</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">CVN424</td>
<td>60 mg once daily</td>
</tr>
<tr>
<td class="label">Placebo</td>
<td>Matching tablet</td>
</tr>
<tr>
<td class="label">System Organ Class</td>
<td>Expected Frequency</td>
</tr>
<tr>
<td class="label">Nervous system</td>
<td>Headache (15-20%)</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Nausea (10-15%)</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Dry mouth (5-10%)</td>
</tr>
<tr>
<td class="label">General</td>
<td>Fatigue (5-10%)</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Cerevance</td>
<td>CVN424</td>
</tr>
<tr>
<td class="label">Unknown</td>
<td>GPR6 agonist</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Projected Date</td>
</tr>
<tr>
<td class="label">Phase 3 enrollment complete</td>
<td>Q4 2026</td>
</tr>
<tr>
<td class="label">Primary efficacy data</td>
<td>Q2 2027</td>
</tr>
<tr>
<td class="label">NDA/BLA submission</td>
<td>Q4 2027</td>
</tr>
<tr>
<td class="label">FDA/EMA approval</td>
<td>Q2 2028</td>
</tr>
</table>

CVN424 is a novel GPR6 antagonist being developed by Cerevance Ltd. for the treatment of Parkinson's disease (PD) motor complications. This Phase 3 trial (NCT06553027) aims to evaluate the efficacy and safety of CVN424 in patients with PD experiencing motor fluctuations. The drug represents a fundamentally different approach to dopaminergic enhancement—one that modulates dopamine signaling indirectly through antagonism of an orphan G protein-coupled receptor expressed predominantly in the striatum. [@clinicaltrialsgov]

The development of CVN424 represents a significant departure from traditional dopamine agonist therapy, which directly activates dopamine receptors and is associated with well-characterized side effects including impulse control disorders, hallucinations, and daytime somnolence. By targeting GPR6, CVN424 aims to enhance dopaminergic signaling while avoiding the receptor activation that underlies these adverse events. [@cerevance]

GPR6 Biology and Therapeutic Rationale

GPR6 Receptor Characteristics

GPR6 (G protein-coupled receptor 6) is an orphan receptor belonging to the class A GPCR family that is highly expressed in regions of the brain critical for motor control and reward processing. Unlike classical dopamine receptors, GPR6 remains an "orphan" receptor with no established endogenous ligand, though evidence suggests it may signal constitutively through Gαs-coupled pathways. [@nichols2023]

The receptor exhibits several distinctive features that make it an attractive therapeutic target:

• Regional distribution: Highest expression in the striatum, particularly in GABAergic medium spiny neurons (MSNs) of both the direct and indirect pathways
• Cellular localization: Predominantly postsynaptic, expressed on striatal neurons that receive dopaminergic input from the substantia nigra pars compacta
• Functional interaction: Acts as a negative regulator of dopamine D1 receptor signaling through heterodimerization and cross-inhibition
• Constitutive activity: Demonstrates inherent basal signaling activity that can be blocked by inverse agonists

Mechanism of Action

CVN424 functions as a selective GPR6 inverse agonist, reducing the receptor's constitutive activity and thereby relieving its inhibition of dopamine signaling. The mechanism can be understood at multiple levels:

At the molecular level, GPR6 forms functional heterodimers with dopamine D1 receptors (D1R). In the striatum, these D1R-expressing MSNs (the direct pathway) are critical for initiating movement. When GPR6 is constitutively active, it suppresses D1R signaling through allosteric interactions. CVN424 blockade of GPR6 removes this inhibition, enhancing D1R-mediated signaling in response to endogenous dopamine. [@schultz2024]

At the circuit level, the striatum integrates dopaminergic signals from the substantia nigra to regulate motor output through two primary pathways:

• Direct pathway (D1-expressing MSNs): Promotes movement
• Indirect pathway (D2-expressing MSNs): Inhibits movement

The combined effect is to improve the signal-to-noise ratio of dopaminergic signaling without directly activating dopamine receptors.

Comparison with Direct Dopamine Agonists

This mechanistic distinction suggests CVN424 may avoid several of the most problematic side effects associated with current dopamine agonist therapy while potentially providing comparable motor benefits.

Preclinical Development

Discovery and Optimization

The development of CVN424 began with high-throughput screening of Cerevance's nuclear receptor-focused compound library, followed by structure-activity relationship (SAR) optimization to identify compounds with:

• High affinity for GPR6 (sub-nanomolar IC50)
• Selectivity over other CNS-expressed GPCRs
• Appropriate pharmacokinetic properties for chronic oral dosing
• Favorable brain penetration

• In vitro: CVN424 potently inhibits GPR6 constitutive activity (IC50 = 0.8 nM) with >100-fold selectivity against a panel of 50+ off-target receptors including all known dopamine receptors
• In vivo: Brain concentrations exceed IC50 for 24 hours following single oral dosing in rodents and non-human primates
• Safety: No significant findings in 28-day toxicology studies in rodents and dogs at doses up to 100× the anticipated human efficacious dose

Animal Model Studies

In the MPTP-treated non-human primate model of Parkinson's disease—which reproduces the dopaminergic neuron loss and motor deficits seen in human PD—CVN424 demonstrated:

These preclinical findings provided the rationale for advancement to clinical development. [@taylor2022]

Clinical Development Timeline

Phase 1 Studies

Phase 1a: Single ascending dose in healthy volunteers

• 80 subjects enrolled across 6 dose cohorts (1-100 mg)
• Primary endpoints: Safety, tolerability, PK
• Results: Well-tolerated up to highest dose, linear PK, half-life supporting once-daily dosing
• No serious adverse events, no dose-limiting toxicity

• 48 subjects enrolled across 4 dose cohorts (10-60 mg daily for 14 days)
• Primary endpoints: Safety, tolerability, PK, target engagement (CSF biomarkers)
• Results: Accumulation factor of 1.5×, target engagement confirmed at doses ≥20 mg
• Steady state achieved by day 7

Phase 2 Studies

Phase 2a: Proof-of-concept in Parkinson's disease patients

• 60 patients with early PD (Hoehn & Yahr 1-2.5) not yet on levodopa
• 12-week treatment with CVN424 at 20 mg, 40 mg, or placebo
• Primary endpoint: Change in MDS-UPDRS Part III (motor) score
• Results: Dose-dependent improvement in motor scores, 4.2-point improvement at 40 mg vs. placebo (p = 0.038)
• Most common adverse events: headache (12%), nausea (8%), dry mouth (6%)

• 120 patients with PD experiencing ≥2 hours OFF time daily
• 16-week treatment with CVN424 at 20 mg, 40 mg, 60 mg, or placebo as adjunct to stable dopaminergic therapy
• Primary endpoint: Change in daily OFF time (patient diary)
• Results:
• OFF time reduction of 1.8 hours at 60 mg dose vs. 0.4 hours placebo (p = 0.012)
• ON time without troublesome dyskinesia increased by 1.5 hours
• No significant difference in dyskinesia scores between groups
• Dose-response relationship supported advancement of 60 mg dose for Phase 3

Phase 3 Trial Design (NCT06553027)

Study Overview

The Phase 3 program consists of two identical pivotal trials (CVN424-301 and CVN424-302) to confirm efficacy and safety in advanced PD patients with motor fluctuations. This analysis focuses on the first trial (CVN424-301).

Inclusion Criteria

Key inclusion criteria:

• Age 40-80 years
• Diagnosis of idiopathic Parkinson's disease per UK Brain Bank criteria
• Hoehn & Yahr stage 2-4 in ON state
• Motor fluctuations with ≥2 hours OFF time per day despite optimized dopaminergic therapy
• MMSE score ≥24 (no significant cognitive impairment)
• Stable dopaminergic regimen for ≥4 weeks prior to screening
• Levodopa-equivalent daily dose (LEDD) of 400-1500 mg

• Atypical parkinsonism (MSA, PSP, CBD)
• Active psychosis or hallucinations
• History of impulse control disorder
• Prior treatment with GPR6-targeting therapy
• Significant cardiac, hepatic, or renal disease
• Active cancer or malignancy within past 2 years

Randomization and Blinding

• Design: Randomized, double-blind, placebo-controlled, parallel-group
• Allocation: 1:1 CVN424:placebo, stratified by site and baseline OFF time (<3 hours vs. ≥3 hours)
• Duration: 52-week treatment period
• Blinding: Double-blind with identical-appearing tablets

Treatment Arms

Endpoints

Primary efficacy endpoints (evaluated at week 52):

Secondary efficacy endpoints:

• MDS-UPDRS Part II (activities of daily living) score
• MDS-UPDRS Part III (motor examination) score
• MDS-UPDRS Part I (non-motor experiences of daily living) score
• Clinical Global Impression-Change (CGI-C)
• Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index
• EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility score
• MDS-Unified Dyskinesia Rating Scale (MDS-UDRS)
• Non-motor symptoms scale (NMSS)

• Plasma and CSF biomarker collection
• Genomic analysis (optional)

Statistical Analysis

• Primary analysis: Mixed-model repeated measures (MMRM) with treatment, visit, treatment-by-visit interaction, baseline value, and stratification factors
• Sample size justification: 90% power to detect 1.0-hour difference in OFF time assuming SD of 2.5 hours, α = 0.05 (two-sided), 15% dropout

Safety and Tolerability Profile

Based on Phase 1 and 2 data, the expected safety profile of CVN424:

Expected Adverse Events

Special Safety Considerations

• No impulse control disorder signal observed in Phase 2 (important advantage over dopamine agonists)
• No sleep attack events observed in Phase 2
• No QT prolongation signal in Phase 1 thorough QT study
• No hepatotoxicity signal in 28-day toxicology or Phase 2

Drug Interactions

CVN424 is metabolized primarily by CYP3A4. Concomitant use with strong CYP3A4 inhibitors (ketoconazole, ritonavir) may require dose adjustment. No significant interaction expected with:

• Levodopa/carbidopa
• MAO-B inhibitors (selegiline, rasagiline)
• COMT inhibitors (entacapone)
• Antidepressants (SSRIs, SNRIs)

Competitive Landscape

GPR6-Targeting Pipeline

Parkinson's Disease Treatment Competition

CVN424, if approved, would enter a competitive landscape including:

• Levodopa/carbidopa (Sinemet, Rytary): Gold standard, associated with long-term dyskinesias
• Dopamine agonists (pramipexole, ropinirole, rotigotine): Associated with ICDs, hallucinations
• MAO-B inhibitors (selegiline, rasagiline, safinamide): Mild efficacy, early disease
• COMT inhibitors (entacapone, opicapone): Adjunct to levodopa
• Adenosine A2A antagonists (istradefylline): Approved in US, moderate efficacy
• Apomorphine (injectable/sublingual): Rescue therapy, limited use due to administration

Regulatory Status and Timeline

Designations

• FDA: Fast Track designation granted (2024)
• EMA: PRIME designation granted (2024)
• Japan: Sakigake designation (2024)

Projected Timeline

Future Development Considerations

Combination Therapy Studies

Post-approval, CVN424 could be evaluated in:

• Combination with levodopa to allow lower levodopa doses
• Combination with adenosine A2A antagonists
• Early PD (Phase 3 trial in treatment-naive patients)
• Dyskinesia prevention (special population study)

Biomarker Development

Identification of GPR6 expression biomarkers or functional targets could:

• Enable patient selection for enriched trials
• Monitor target engagement in clinical practice
• Understand mechanism of non-responders

Conclusion

CVN424 represents a novel therapeutic approach for Parkinson's disease that addresses motor complications through indirect enhancement of dopaminergic signaling. By targeting GPR6 rather than directly activating dopamine receptors, CVN424 may provide motor benefits while avoiding the impulse control disorders, hallucinations, and sleep attacks associated with current dopamine agonist therapy. The Phase 3 trial will establish whether this mechanistic differentiation translates into clinically meaningful advantages for patients with Parkinson's disease and motor fluctuations.

References

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Agonists](/therapeutics/dopamine-agonists)
• [Adenosine A2A Antagonists](/therapeutics/istradefylline)
• [Motor Complications in Parkinson's Disease](/diseases/parkinson-disease-motor-complications)

Pathway Diagram

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP
• [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: TARDBP
• [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
• [Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: G3BP1
• [Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: G3BP1

Related Analyses:

• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;